Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies
Abstract
Purpose To evaluate the changes in the volume of rectovaginal endometriotic nodules infiltrating the rectum during 12-month treatment with hormonal therapies.Materials and methods This prospective, non-randomized, self-controlled clinical trial included patients with rectovaginal endometriotic nodules infiltrating at least the muscularis propria of the rectum, who received one of the following therapies: norethisterone acetate, triptorelin and tibolone, norethisterone acetate and letrozole, desogestrel, sequential oral contraceptive pill. The volume of the nodules was determined by virtual organ computer-aided analysis (VOCAL, GE Healthcare, USA) at baseline and after 6 and 12 months of treatment.Results Eighty-three women (90.2 %) completed the 12-month treatment. When compared with baseline values, the volume of the nodules decreased at 6-month (p < 0.001) and 12-month treatment (p < 0.001). After 12-month treatment, the volume of the nodules decreased in all study groups. The volume of the nodules decreased during therapy in 68 women (73.9 %) and increased in 11 women (12.0 %).Conclusion 12-month administration of hormonal therapies reduces the volume of rectovaginal endometriotic nodules infiltrating the rectum in the majority of cases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The reduction in lesion volume with estroprogestins or progestins is not predictable and not significant in the vast majority of cases.
“The reduction in lesion volume is not predictable and not significant in the vast majority of cases. Conflicting results have been observed [77,78,79,80,81,82,86,87,88].”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [86]
These two studies clearly confirmed that GnRH antagonist suppresses ovarian function in a dose-dependent manner, allowing modulation of E2 levels which, according to the threshold hypothesis, may provide relief from endometriosis-associated pain while reducing side effects caused by extreme hypoestrogenism.
“These two studies clearly confirmed that GnRH antagonist suppresses ovarian function in a dose-dependent manner, allowing modulation of E2 levels which, according to the threshold hypothesis [86], may provide relief from endometriosis-associated pain while reducing side effects caused by extreme hypoestrogenism.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [86]
Four additional studies investigating more than 200 patients showed comparable results in pain reduction between AIs vs. GnRHa or AI plus NETA vs. NETA alone or AI plus GnRH.
“Four additional studies investigating more than 200 patients showed comparable results in terms of pain reduction between AIs vs. GnRHa or AI plus NETA vs. NETA alone or AI plus GnRH ( 29 – 32 ), making less clear the clinical added value of AI over conventional, first-line, treatments.”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [31]
The citation lists haven’t been fetched yet
References 32 · Cited by 57
- Authors
- Ferrero, S., Leone Roberti Maggiore, U., Scala, C., Di Luca, M., Venturini, P. L., & Remorgida, V.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Venue
- Archives of Gynecology and Obstetrics
- Published
- 2012-10-09
- Volume
- 287
- Issue
- 3
- Pages
- 447-453
- ISSN
- 0003-9128 (ISSN-L)
- 0932-0067
- 1432-0711
- OpenAlex
- W2072547957
- Cited by
- 57
- References
- 32
- Citations by year
- 2026: 2 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 11 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 2
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Archives of Gynecology and Obstetrics (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
- Keywords
- rectovaginal endometriosis, endometriotic nodules, rectal endometriosis, hormone therapy, norethisterone acetate, triptorelin, tibolone, letrozole, desogestrel, nodule volume, VOCAL
- MeSH terms
- Letrozole, Norethindrone Acetate, Adult, Calcium, Cholecalciferol, Contraceptives, Oral, Sequential, Contraceptives, Oral, Synthetic, Endometriosis, Female, Humans, Image Processing, Computer-Assisted, Nitriles, Norethindrone, Norpregnenes, Prospective Studies, Rectal Diseases, Triazoles, Ultrasonography, Vaginal Diseases, Vitamins, Treatment Outcome, Desogestrel, Triptorelin Pamoate, Estrogen Receptor Modulators, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
